These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 23362511

  • 1. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [Abstract] [Full Text] [Related]

  • 2. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK, ADDUCE consortium.
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [Abstract] [Full Text] [Related]

  • 4. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, Rossi F, Capuano A.
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [Abstract] [Full Text] [Related]

  • 5. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
    Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, Brodziak K, Biederman J, Wilens TE.
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):493-9. PubMed ID: 19877973
    [Abstract] [Full Text] [Related]

  • 6. Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
    Germinario EA, Arcieri R, Bonati M, Zuddas A, Masi G, Vella S, Chiarotti F, Panei P, Italian ADHD Regional Reference Centers.
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):440-7. PubMed ID: 24024538
    [Abstract] [Full Text] [Related]

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 8. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

  • 9. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 10. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A, Scavone C, Rafaniello C, Arcieri R, Rossi F, Panei P.
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [Abstract] [Full Text] [Related]

  • 11. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P, Sikirica V, Chen YJ, Curtice TG, Makin C.
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [Abstract] [Full Text] [Related]

  • 12. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P.
    CNS Drugs; 2015 Sep; 29(10):865-77. PubMed ID: 26293742
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G, Besag FM.
    Drug Saf; 2010 Oct 01; 33(10):821-42. PubMed ID: 20812768
    [Abstract] [Full Text] [Related]

  • 14. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L, Zhou P, Zhu L, Zhang Y, Yang T, Zhao Q, Chen J, Li T, Cheng Q, Chen L.
    Pharmacol Biochem Behav; 2021 Sep 01; 208():173225. PubMed ID: 34217783
    [Abstract] [Full Text] [Related]

  • 15. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B, Karakaya E, Oztop DB.
    J Child Adolesc Psychopharmacol; 2015 Aug 01; 25(6):494-500. PubMed ID: 26218871
    [Abstract] [Full Text] [Related]

  • 16. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R.
    J Clin Psychopharmacol; 2013 Dec 01; 33(6):766-74. PubMed ID: 23963057
    [Abstract] [Full Text] [Related]

  • 17. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.
    Health Technol Assess; 2006 Jul 01; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [Abstract] [Full Text] [Related]

  • 18. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
    Didoni A, Sequi M, Panei P, Bonati M, Lombardy ADHD Registry Group.
    Eur J Clin Pharmacol; 2011 Oct 01; 67(10):1061-7. PubMed ID: 21538145
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q, Zhang H, Fang Q, Qin L.
    J Clin Exp Neuropsychol; 2017 Nov 01; 39(9):854-865. PubMed ID: 28052720
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky MJ, Strom BL.
    Pharmacoepidemiol Drug Saf; 2010 Sep 01; 19(9):934-41. PubMed ID: 20623519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.